Spots Global Cancer Trial Database for dutasteride
Every month we try and update this database with for dutasteride cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer | NCT00853697 | Prostate Cancer Castration-resi... | testosterone (A... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Economic Analyses of the REDUCE Trial | NCT01337258 | Neoplasms, Pros... Benign Prostati... Cancer | Dutasteride Placebo | 50 Years - 75 Years | GlaxoSmithKline | |
| Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Androgen Ablation Therapy for Prostate Cancer | NCT00553878 | Prostate Cancer | Dutasteride | 45 Years - 80 Years | Canadian Urology Research Consortium | |
| Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer | NCT01342367 | Prostate Cancer | Bicalutamide Dutasteride Finasteride Radiation | 18 Years - | University of Chicago | |
| Phase II Dutasteride in Combination With CAB vs CAB in SDC | NCT05513365 | Salivary Duct C... | Goserelin 10.8 ... Bicalutamide 50... Dutasteride 0.5... | 18 Years - | Radboud University Medical Center | |
| Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer | NCT01393730 | Prostate Cancer | Abiraterone ace... Dutasteride Prednisone | 18 Years - | Dana-Farber Cancer Institute | |
| Dutasteride in Treating Patients With Recurrent Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy | NCT00403000 | Prostate Cancer | dutasteride | 18 Years - | Roswell Park Cancer Institute | |
| Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer | NCT01342367 | Prostate Cancer | Bicalutamide Dutasteride Finasteride Radiation | 18 Years - | University of Chicago | |
| Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer | NCT00673127 | Prostate Cancer | Ketoconazole, H... | 18 Years - | Dana-Farber Cancer Institute | |
| "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk | NCT00056407 | Neoplasms, Pros... | Dutasteride Placebo | 50 Years - 75 Years | GlaxoSmithKline | |
| Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer | NCT01547299 | Prostate Cancer | Enzalutamide Leuprolide Dutasteride | 18 Years - | Pfizer | |
| Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer | NCT00985738 | Prostate Cancer | Dutasteride Placebo | 40 Years - 85 Years | University of Colorado, Denver | |
| Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer | NCT00668642 | Prostate Cancer | Dutasteride Placebo | 18 Years - | NorthShore University HealthSystem | |
| Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP) | NCT05705700 | Prostate Cancer | Dutasteride Abiraterone | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer | NCT00706966 | Nonmalignant Ne... Prostate Cancer | dutasteride | - | University of California, San Francisco | |
| Phase II Dutasteride in Combination With CAB vs CAB in SDC | NCT05513365 | Salivary Duct C... | Goserelin 10.8 ... Bicalutamide 50... Dutasteride 0.5... | 18 Years - | Radboud University Medical Center | |
| Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer | NCT00953576 | Prostate Cancer | ketoconazole hydrocortisone dutasteride lapatinib | 18 Years - | Dana-Farber Cancer Institute | |
| Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy | NCT00470834 | Neoplasms, Pros... | dutasteride placebo bicalutamide | 40 Years - 90 Years | GlaxoSmithKline | |
| For Cause Prostate Biopsy in REDUCE Population Trial | NCT01529086 | Prostate Cancer | 50 Years - 75 Years | The Cleveland Clinic | ||
| Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation | NCT00805701 | Prostate Cancer | avodart Placebo | 35 Years - 90 Years | Bay State Clinical Trials, Inc. | |
| A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy | NCT02159690 | Prostate Cancer Localized Prost... | Enzalutamide Abiraterone ace... Prednisone Dutasteride Degarelix | 18 Years - | Johns Hopkins University | |
| Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation | NCT00805701 | Prostate Cancer | avodart Placebo | 35 Years - 90 Years | Bay State Clinical Trials, Inc. | |
| ARI103094-Follow-Up Study for REDUCE Study Subjects | NCT00883909 | Neoplasms, Pros... | dutasteride | 50 Years - | GlaxoSmithKline | |
| Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies | NCT01594502 | Prostate Cancer | Dutasteride Placebo | 50 Years - 75 Years | University of Illinois at Chicago | |
| Economic Analyses of the REDUCE Trial | NCT01337258 | Neoplasms, Pros... Benign Prostati... Cancer | Dutasteride Placebo | 50 Years - 75 Years | GlaxoSmithKline | |
| Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer | NCT00985738 | Prostate Cancer | Dutasteride Placebo | 40 Years - 85 Years | University of Colorado, Denver | |
| For Cause Prostate Biopsy in REDUCE Population Trial | NCT01529086 | Prostate Cancer | 50 Years - 75 Years | The Cleveland Clinic | ||
| MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer | NCT00706966 | Nonmalignant Ne... Prostate Cancer | dutasteride | - | University of California, San Francisco | |
| Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer | NCT00375765 | Benign Prostati... Prostate Cancer | Dutasteride | 50 Years - | GlaxoSmithKline | |
| Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men | NCT00363311 | Neoplasms, Pros... | Dutasteride Matching placeb... | 50 Years - 80 Years | GlaxoSmithKline |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
